Tani T, Endo Y, Yoshioka T, Aoki H, Matsuda K, Numa K, Hanasawa K, Kodama M
First Department of Surgery, Shiga University of Medical Science, Japan.
Prog Clin Biol Res. 1990;337:213-20.
It goes without saying that post-surgical hepatic failure must be treated. But today, the prognosis is very poor. The reasons for this are that HF is usually accompanied by hemostatic disorders and PHF, and the patients have fresh wounds and are under surgical stress. Moreover, there is no treatment, except PE, and this requires an anticoagulant. Nafamostat Mesilate (FUT-175) was invented as a serine protease inhibitor. It is short acting, and its degradation does not require the liver. FUT-175 was applied as an anticoagulant to 15 PHF patients with bleeding. There were no side effects and no aggravation of bleeding. Based on these results, FUT-175 is thought to be an ideal anticoagulant.
不言而喻，术后肝衰竭必须加以治疗。但如今，其预后非常糟糕。原因在于肝衰竭通常伴有止血障碍和术后肝衰竭，且患者有新伤口并处于手术应激状态。此外，除了血浆置换外没有其他治疗方法，而这需要一种抗凝剂。甲磺酸萘莫司他（FUT - 175）作为一种丝氨酸蛋白酶抑制剂被研发出来。它作用时间短，其降解不需要肝脏参与。FUT - 175被用作抗凝剂应用于15例有出血症状的术后肝衰竭患者。未出现副作用，出血情况也未加重。基于这些结果，FUT - 175被认为是一种理想的抗凝剂。
